Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics (2021)
- Authors:
- USP affiliated authors: SAGGIORO, FABIANO PINTO - SVOI ; REIS, RODOLFO BORGES DOS - FMRP ; SQUIRE, JEREMY ANDREW - FMRP ; SOUZA, LUIZ PAULO CHAVES DE - FMRP ; MELO, CAMILA MORAIS - FMRP
- Unidades: SVOI; FMRP
- DOI: 10.3390/genes12121900
- Subjects: NEOPLASIAS PROSTÁTICAS; IMUNOTERAPIA; ONCOGENES; GENES SUPRESSORES DE TUMOR; MUTAÇÃO GENÉTICA; BIOMARCADORES
- Keywords: Castrate-resistant prostate cancer; Immunotherapy; Immune evasion; Tumor microenvironment; Oncogenes; Tumor suppressor genes; Mouse models of cancer; Epigenomics; Plasticity; Chromatin modification
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
SOUZA, Luiz Paulo Chaves de et al. Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics. Genes, v. 12, n. 12, p. 1-18, 2021Tradução . . Disponível em: https://doi.org/10.3390/genes12121900. Acesso em: 02 abr. 2026. -
APA
Souza, L. P. C. de, Melo, C. M., Saggioro, F. P., Reis, R. B. dos, & Squire, J. A. (2021). Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics. Genes, 12( 12), 1-18. doi:10.3390/genes12121900 -
NLM
Souza LPC de, Melo CM, Saggioro FP, Reis RB dos, Squire JA. Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics [Internet]. Genes. 2021 ; 12( 12): 1-18.[citado 2026 abr. 02 ] Available from: https://doi.org/10.3390/genes12121900 -
Vancouver
Souza LPC de, Melo CM, Saggioro FP, Reis RB dos, Squire JA. Epithelial–mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics [Internet]. Genes. 2021 ; 12( 12): 1-18.[citado 2026 abr. 02 ] Available from: https://doi.org/10.3390/genes12121900 - Emerging role of PTEN loss in evasion of the immune response to tumours
- Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer
- The role of somatic mutations on the immune response of the tumor microenvironment in prostate cancer
- ZEB1 expression is associated with the PTEN loss and TMPRSS2 ERG fusion immune evasion phenotype in prostate cancer
- TCGA analysis identifies distinct genomic features of oncogenic progression and outcome associated with hemizygous PTEN loss tumors
- Analysis of the relationships between ZEB1, PTEN loss, TMPRSS2-ERG fusion and immune response biomarkers in Prostate Cancer
- PTEN loss associates with STAT1/3 expression and intra-tumoral CD8+ density in prostate cancer
- Quantitative measurement of PTEN loss improves risk assessment in prostate cancer
- Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN)
- Investigating the role of SNAI1 and ZEB1 expression in prostate cancer progression and immune modulation of the tumor microenvironment
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003074056.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
